Le Lézard
Classified in: Health
Subject: SVY

United States Diagnostic Imaging Markets, 2019-2024: Market Players are Focusing on R&D to Develop Technologically Advanced Products


DUBLIN, March 22, 2019 /PRNewswire/ -- The "Us Diagnostic Imaging Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The major factors for the growth of the US diagnostic imaging market include the technological advancement in imaging modalities, growing awareness regarding preventive care, the rising number of diagnostic imaging centers, increasing prevalence of chronic diseases, and increasing geriatric population.

The United States is expected to experience an accelerated rate of aging population, as compared to other developed countries. The growth in aging population leads to an increase in the demand for imaging services, since the elderly population is more prone to chronic diseases.

According to the National Institutes of Health (NIH) Data, patients aged 65 and above undergo diagnostic imaging two or more times more than the younger population. The number of times women undergo diagnostic imaging is expected to be slightly higher than that of men. The proportion of the older population in the United States, with favorable insurance coverage policies, is likely to drive the market. According to the estimates of the American Cancer Society, in 2018, there were 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths in the United States. The rising number of cases of cancer are creating tremendous opportunities for market players.

Scope of the Report

As per the scope of the report, the US diagnostic imaging market covers diagnostic imaging used to take images of the internal structure of the human body using electromagnetic radiation, the for accurate diagnosis of the patient. It has vast applications in a variety of oncological, orthopedic, gastro- and gynecological fields. The market is segmented by product, application, end user, and geography.

Key Market Trends

Magnetic Resonance Imaging (MRI) Segment by Product is Expected to Account for the Largest Market Share during the Forecast Period

The MRI segment is set to dominate the US diagnostic imaging market. The factors attributing to the high growth of MRI in the country are growing technological advancements in MRI modality and widening the application of MRI in the medical field. As per the estimates of the Organisation for Economic Co-operation and Development (OECD), in 2017, in the United States, there were a total number of 111 MRI exams per 1000 inhabitants. In order to increase awareness among physicians, some of the market players are providing training courses.

For instance, Bruker BioSpin is one of the companies that is offering training courses for MRI customers in Europe and the United States. Under this course, it covers a wide range of applications from introductory classes to advanced operator courses. Thus, owing to the rising prevalence of chronic diseases and technological advancements, the market is expected to witness a healthy CAGR over the forecast period.

Competitive Landscape

The US diagnostic imaging market is consolidated, owing to the presence of few major players. The market players are focusing on R&D to develop technologically advanced products, in order to reduce the cost and side effects associated with the products. The barriers for the new entrants are high in this industry, and hence, few major market players hold the maximum market share.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancement in Imaging Modalities
4.2.2 Growing Awareness Regarding Preventive Care
4.2.3 Rising Number of Diagnostic Imaging Centers
4.2.4 Increasing Prevalence of Chronic Diseases and Rising Geriatric Population
4.3 Market Restraints
4.3.1 Dearth of Radiologists
4.3.2 Reduction in Reimbursement Rate
4.4 Porter's Five Forces Analysis

5 Market Segmentation
5.1 By Product
5.1.1 X-ray Radiology
5.1.2 Ultrasound
5.1.3 Magnetic Resonance Imaging (MRI)
5.1.4 Mammography
5.1.5 Computed Tomography
5.1.6 Nuclear Medicine
5.1.6.1 Positron Emission Tomography (PET)
5.1.6.2 Single-photon Emission Computerized Tomography (SPECT)
5.2 By Application
5.2.1 Cardiology
5.2.2 Oncology
5.2.3 Neurology
5.2.4 Orthopedic
5.2.5 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostic Centers
5.3.3 Other End Users

6 Competitive Landscape
6.1 Company Profiles
6.1.1 Canon Medical Systems Corporation
6.1.2 Carestream Health Inc.
6.1.3 Esaote SpA
6.1.4 FUJIFILM Holdings Corporation
6.1.5 GE Healthcare
6.1.6 Hitachi Medical Systems
6.1.7 Hologic Corporation
6.1.8 Koninklijke Philips NV
6.1.9 Shimadzu Medical
6.1.10 Siemens Medical Solutions USA, Inc.

7 Market Opportunities and Future Trends

For more information about this report visit https://www.researchandmarkets.com/research/tbqns4/united_states?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 04:40
TC BioPharm (TCB), a developer of allogeneic CAR-T immuno-oncology products, and leaders in Gamma Delta T (GDT) cell therapies, today announced it has initiated a Phase I clinical study of TCB002, an allogeneic cell therapy...

at 04:35
Aptorum Group Limited today announced the establishment of a new subsidiary group, Smart Pharma ("SmartP"), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to...

at 04:33
During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives and took several steps towards the commercialization of IMMraytm PanCan-d, our diagnostic test...

at 04:20
Aptorum Group Limited ("Aptorum" or the "Company"), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the...

at 04:10
According to a new joint study conducted by scientists at Global Lyme Alliance (GLA) and Brown University, more than two million people in the United States could suffer profound disability from post treatment Lyme disease syndrome (PTLD) by the year...

at 04:00
Emendo Biotherapeutics Inc today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of the transaction, Emendo will receive an investment in convertible notes from Takeda Ventures, Inc.,...



News published on 22 march 2019 at 18:45 and distributed by: